While regulatory agency guidelines do not mandate a specific committee composition, all Advarra DMCs follow industry best practice and are typically comprised of: Five or more total members who collectively have the expertise to assess the interim statistical data and risks associated with the clinical trial. At least two members who are experienced biostatisticians. At least one member with specific scientific and medical expertise to evaluate safety. At least one non-scientifically trained member to represent the general perspective of research participants. DMC membership varies based on the nature of the protocol, and final membership demographics are outlined in the DMC charter in collaboration with the sponsor or CRO.